ArticleAnnals of biomedical engineering2026
Development and Pre-clinical Feasibility of a Catheter-Based Platform for Interventional Phase-0 Drug Response Measurements.
Article in Annals of biomedical engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeTo develop and validate a percutaneous Interventional Drug Response Assay (IDRA) catheter capable of intratumoral drug microdosing, adhesive stabilization, and subsequent biopsy retrieval of drug-exposed tissue, enabling minimally invasive in situ drug response measurements.
methodsThe IDRA catheter was designed as a modular platform allowing image-guided insertion, adhesive-based stabilization, microdose drug delivery into four discrete tissue regions, and suction-assisted biopsy retrieval. Feasibility and functionality were assessed across three ex vivo models: a gelatin phantom (n = 15), pork loin (n = 15), and rabbit VX-2 tumors (n = 15), as well as a rabbit VX-2 in vivo model (n = 2). Endpoints included proportion of drug reservoirs yielding intact tissue, sample thickness, and stabilization force. Success was defined as retrieval of ≥ 75% of drug regions with ≥ 3 drug sites per catheter and stabilization within a target force range of 1.5-4 N.
resultsEx vivo success rates were 100% (15/15 catheters) in phantom, 80% (12/15) in pork loin, and 80% (12/15) in VX-2 tumors. Mean tissue thickness exceeded 500 µm in all models (phantom: 860 ± 233 µm; loin: 589 ± 261 µm; VX-2: 637 ± 271 µm). Stabilization forces were within the target range across all tissue types (phantom: 3.4 ± 0.5 N; loin: 2.5 ± 0.6 N; VX-2: 2.8 ± 0.6 N). In vivo, 3-4 drug regions were successfully retrieved per catheter without complications.
conclusionThe IDRA catheter achieved predefined functional endpoints across ex vivo and in vivo models, demonstrating early mechanical and procedural feasibility. If biologically validated, this could serve as a non-surgical platform for microdose-based early human drug response and biomarker testing and personalized oncology applications.
Indexed as
Identifiers
41906015What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.